FARN Stock Overview
Operates as a clinical stage drug discovery and development company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Faron Pharmaceuticals Oy Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1.50 |
| 52 Week High | UK£3.70 |
| 52 Week Low | UK£0.85 |
| Beta | 0.33 |
| 11 Month Change | -29.91% |
| 3 Month Change | -11.76% |
| 1 Year Change | -43.40% |
| 33 Year Change | -55.88% |
| 5 Year Change | -11.76% |
| Change since IPO | -45.95% |
Recent News & Updates
Shareholder Returns
| FARN | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -7.7% | -6.0% | -0.3% |
| 1Y | -43.4% | -22.4% | 6.1% |
Return vs Industry: FARN underperformed the UK Biotechs industry which returned -22.4% over the past year.
Return vs Market: FARN underperformed the UK Market which returned 6.1% over the past year.
Price Volatility
| FARN volatility | |
|---|---|
| FARN Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: FARN's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: FARN's weekly volatility has decreased from 15% to 10% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 34 | Juho Jalkanen | www.faron.com |
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company is also developing bexmarilimab, which is in phase 2 clinical trial for indications of solid tumors; and in phase 1 clinical trial for indications of acute myeloid leukemia and myelodysplastic syndromes.
Faron Pharmaceuticals Oy Fundamentals Summary
| FARN fundamental statistics | |
|---|---|
| Market cap | UK£156.94m |
| Earnings (TTM) | -UK£26.42m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.9x
P/E RatioIs FARN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FARN income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €31.61m |
| Earnings | -€31.61m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.30 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 897.6% |
How did FARN perform over the long term?
See historical performance and comparison